We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-6.2%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.77B
AUM Growth
-$356M
Cap. Flow
-$1.35B
Cap. Flow %
-28.26%
Top 10 Hldgs %
39.93%
Holding
155
New
23
Increased
16
Reduced
21
Closed
28

Top Buys

Rank Stock Value
1
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$89.6M
2
AHCO icon
AdaptHealth
AHCO
+$49.8M
3
ESPR
Esperion Therapeutics
ESPR
+$40M
4
XLO icon
Xilio Therapeutics
XLO
+$36.7M
5
FIGS icon
FIGS
FIGS
+$27.3M

Top Sells

Rank Stock Value
1
BDSI
BioDelivery Sciences International, Inc.
BDSI
+$30.8M
2
MOH icon
Molina Healthcare
MOH
+$28.8M
3
CYTK icon
Cytokinetics
CYTK
+$28.1M
4
XLRN
Acceleron Pharma
XLRN
+$25M
5
FATE icon
Fate Therapeutics
FATE
+$21.5M

Sector Composition

Rank Sector Weight
1 Healthcare 62.96%
2 Financials 1.4%
3 Consumer Discretionary 0.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TMPMW
101
DELISTED
Turmeric Acquisition Corp. Warrant
TMPMW
$170K ﹤0.01%
+250,000
New +$162K
REVHW
102
DELISTED
Revolution Healthcare Acquisition Corp. SAIL Warrant.
REVHW
$150K ﹤0.01%
200,000
– –
BDSI
103
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$91K ﹤0.01%
29,204
-9,141,495
-100% -$30.8M
OHPAW
104
DELISTED
Orion Acquisition Corp. Warrant
OHPAW
$81K ﹤0.01%
125,000
– –
WINT
105
DELISTED
Windtree Therapeutics
WINT
– –
0
– –
AUPH icon
106
PUT
Aurinia Pharmaceuticals
AUPH
$1.96B
– –
-425,300
Closed -$9.41M
AVAH icon
107
Aveanna Healthcare
AVAH
$2.11B
– –
-1,013,007
Closed -$8.12M
JBIO
108
Jade Biosciences
JBIO
$1.21B
– –
-20,408
Closed -$15M
BDTX icon
109
Black Diamond Therapeutics
BDTX
$99.1M
– –
-760,128
Closed -$6.43M
CVRX icon
110
CVRx
CVRX
$129M
– –
-413,747
Closed -$6.84M
ERAS icon
111
Erasca
ERAS
$6.55B
– –
-786,660
Closed -$16.7M
FATE icon
112
Fate Therapeutics
FATE
$283M
– –
-362,000
Closed -$21.5M
GHRS icon
113
GH Research
GHRS
$1.9B
– –
-405,416
Closed -$8.94M
IRTC icon
114
iRhythm Holdings
IRTC
$3.69B
– –
-60,271
Closed -$3.53M
CYPH
115
Cypherpunk Technologies Inc
CYPH
$66.7M
– –
-400,000
Closed -$16M
OLMA icon
116
Olema Pharmaceuticals
OLMA
$1.05B
– –
-271,191
Closed -$7.47M
RXST icon
117
RxSight
RXST
$233M
– –
-900,000
Closed -$11.4M
TALK icon
118
Talkspace
TALK
$874M
– –
-750,000
Closed -$2.74M
TIL icon
119
Instil Bio
TIL
$48.5M
– –
-55,787
Closed -$19.9M
TYRA icon
120
Tyra Biosciences
TYRA
$1.85B
– –
-625,000
Closed -$11M
LENZ
121
LENZ Therapeutics
LENZ
$179M
– –
-129,473
Closed -$14.9M
OKUR
122
OnKure Therapeutics
OKUR
$164M
– –
-84,930
Closed -$6.33M
SPRB
123
Spruce Biosciences
SPRB
$116M
– –
-29,333
Closed -$13.2M
HLTH
124
DELISTED
Cue Health Inc. Common Stock
HLTH
– –
-798,867
Closed -$9.44M
EUCRU
125
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
– –
-1,000,000
Closed -$9.95M
2 3 4
5
6

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q4 2021 Portfolio in Review

As of Q4 2021, Deerfield Management held 155 positions worth $4.77B, down 7% from $5.12B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Deerfield Management withdrew a net $1.35B in Q4 2021, closing 28 positions and reducing 21 holdings. Its most notable exit was Acceleron Pharma, an estimated $25M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 66% a quarter earlier, followed by Financials and Consumer Discretionary.

Against the trend, Deerfield Management opened a new position in Esperion Therapeutics worth $25M.

  • Deerfield Management's largest Q4 2021 buy was Esperion Therapeutics: 5,000,000 shares worth $25M.
  • Deerfield Management added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2021, an estimated $89.6M increase.
  • Deerfield Management's biggest Q4 2021 reduction was BioDelivery Sciences International, Inc., cutting an estimated $30.8M.
  • Deerfield Management fully exited Acceleron Pharma in Q4 2021, selling an estimated $25M.
  • Deerfield Management's ten largest holdings make up 40% of its $4.77B portfolio in Q4 2021.
  • Deerfield Management opened 23 new positions and closed 28 in Q4 2021.
  • Deerfield Management's portfolio value fell 7% quarter-over-quarter to $4.77B.

Based on Deerfield Management's 13F filing for Q4 2021, filed 14 Feb 2022.